FDA Approves Generic Liraglutide to Address GLP-1 Drug Shortage
The US Food and Drug Administration (FDA) recently approved liraglutide to treat type 2 diabetes in combination with diet and exercise, which makes it the first generic version of Victoza and the second glucagon-like peptide-1 (GLP-1) receptor agonist authorized as a generic drug.
The US Food and Drug Administration (FDA) recently approved liraglutide to treat type 2 diabetes in combination with diet and exercise, which makes it the first generic version of Victoza and the second glucagon-like peptide-1 (GLP-1) receptor agonist authorized as a generic drug.
